Pakkaus 10 ampullia5 varastossaSäästä 17 %Retatrutide 60 mg
Tri-agonisti GLP-1 / GIP / glukagoni-tutkimuspeptidi
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Vain tutkimuskäyttöön. Tämä yhdiste myydään tiukasti in vitro -tutkimukseen ja laboratoriotarkoituksiin, eikä se ole tarkoitettu ihmisravinnoksi tai terapeuttiseen käyttöön. Ostamalla vahvistat olevasi pätevä tutkija ja hyväksyt täyden vastuuvapauslausekkeemme.
Vain 5 pakkausta jäljellä
Kolmen reseptorin agonisti-tutkimuspeptidi, jota on tutkittu GLP-1-, GIP- ja glukagonisignalointireittien yhdistettyjen vaikutusten osalta metabolisissa tutkimussovelluksissa.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mekanismi
Tutkittu GLP-1-, GIP- ja glukagonireseptorien samanaikaisen agonismin osalta. Tutkimus liittyy metabolisen nopeuden, kylläisyyden ja energiankulutuksen merkkeihin tutkimuspopulaatioissa.
HPLC-varmennettu ≥99 % puhtausspesifikaatiota vasten. Riippumattomasti testattu akkreditoiduissa kolmannen osapuolen laboratorioissa.
Retatrutide — usein kysytyt kysymykset
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Retatrutide liittyvät oppaat
Tutkijat tutkivat myös
Pakkaus 10 ampulliaSäästä 22 %MOTS-c
Lyofilisoitu jauhe10 mg · 2 strengths
Mitokondrioperäinen metabolinen peptidi
2 stackissa
Pakkaus 10 ampulliaSäästä 16 %5-Amino-1MQ
Lyofilisoitu jauhe50 mg · 3 strengths
NNMT-estäjä, tutkimusyhdiste
Pakkaus 10 ampulliaSäästä 15 %L-Carnitine
Sterile solution10 ml × 600 mg/ml
Mitokondriaalinen rasvahappokuljetin
1 stackissa